Mazziotta Francesco, Cecconi Nadia, Iovino Lorenzo, Cervetti Giulia, Petrini Mario
Genomec School of Doctorate, University of Siena, Siena, ITA.
Clinical and Experimental Medicine, University of Pisa, Pisa, ITA.
Cureus. 2019 Sep 12;11(9):e5630. doi: 10.7759/cureus.5630.
Acquired Hemophilia A (AHA) is a rare disease caused by anti-factor VIII autoantibodies. It is usually characterized by clinically significant bleeding at the onset and requires prompt hemostatic and immunosuppressive therapies. Due to its rarity and the lack of randomized trials, its treatment is a great challenge, especially in the relapse/refractory setting. This report presents the case of a patient diagnosed with chronic lymphocytic leukemia who developed a steroid-resistant AHA, successfully managed with aggressive immunosuppressive therapy.
获得性血友病A（AHA）是一种由抗凝血因子VIII自身抗体引起的罕见疾病。其通常的特征是发病时出现具有临床意义的出血，需要迅速进行止血和免疫抑制治疗。由于其罕见性以及缺乏随机试验，其治疗是一项巨大挑战，尤其是在复发/难治性情况下。本报告介绍了一例被诊断为慢性淋巴细胞白血病且发生了类固醇抵抗性AHA的患者，该患者通过积极的免疫抑制治疗成功得到了处理。
